Mandate

Vinge advises FSN Capital L.P. II et al. on divestment of the CTEK/Creator Group

June 09, 2011

Vinge is advising FSN Capital L.P. II et al. in connection with the divestment of the CTEK/Creator Group to Altor Fund III.

The CTEK/Creator group is the world’s premier manufacturer of advanced battery chargers, sold under inter alia the "CTEK" brand, and a provider of consulting services related to product development under the “Creator” brand. CTEK is, in addition to sales under its own brand, delivering battery chargers to well renowned brands such as Rolls Royce, Ferrari, Porsche, Bentley, Mercedes-Benz, BMW, Lexus, Lamborghini, Alfa Romeo, Audi, Corvette, Maserati, Scania and Yamaha.

Since the investment by FSN Capital L.P. II in April 2008, CTEK has experienced largely increased sales volumes as well as a largely increased EBITDA despite having made significant investments in sales & marketing, R&D and the overall organization.

Closing of the transaction is subject to applicable competition law approvals.

The Vinge team advising FSN Capital L.P. et al. includes partners Bo Adrianzon and Johan Göthberg and inter alia associates Johan Steen, Carolina Walther and Ulrich Ziche.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025